Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Physician Expanded Access to Investigational New Drug Cannabidiol (Epidiolex) for the Treatment of Drug Resistant Epilepsy

Next Previous
Search
Trial Profile

Physician Expanded Access to Investigational New Drug Cannabidiol (Epidiolex) for the Treatment of Drug Resistant Epilepsy

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 18 May 2018 Status changed from recruiting to completed.
    • 24 Dec 2015 Results of 162 patients from 11 sites in the US published in The Lancet Neurology, according to a GW Pharmaceuticals media release.
    • 24 Dec 2015 Results of 162 patients included in the safety and tolerability analysis and 137 patients included in the efficacy analysis from 11 independent epilepsy centres in the US published in a GW Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top